This post was originally published on this site
The FDA advisory committee voted 7 to 4 in favor of the drug, saying data from the clinical study conducted by the company established that the treatment was effective and safe in preventing the lower respiratory tract disease caused by RSV in 60 years and older.
(This story has been corrected to change the voting ratio to “7 to 4” from “7 to 12” in paragraph 2)
